top of page

HIDRADENITIS SUPPURATIVA
CURRENTLY ENROLLING TRIALS

1200px-Incyte_logo.svg.png

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Open for participants age ≥ 18 with a clinical diagnosis of Hidradenitis Suppurativa for at least 3 months prior to screening.

​

Requirements:

  • A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules.

  • Inflammatory lesions affecting at least 2 distinct anatomic areas.

  • Documented history of inadequate response to at least a 3-month course of a conventional systemic therapy (oral antibiotic or biologic drug) for HS, or for whom systemic treatments are otherwise medically inadvisable. 

 

Further inclusion/exclusion criteria apply. If you think you may qualify, please take our pre-screen assessment.

UPCOMING CLINICAL TRIALS

Don't qualify for any of our trials?

Note: If you are under the age of 18, please have your parent/guardian call us directly at 847-663-8530.

Thanks for submitting!

We begin new trials often. If you do not qualify for our current studies, please leave your information, and we'll keep you updated of any upcoming trials that may be right for you.

bottom of page